Background-Overly aggressive diuresis leading to intravascular volume depletion has been proposed as a cause for worsening renal function during the treatment of decompensated heart failure. If diuresis occurs at a rate greater than extravascular fluid can refill the intravascular space, the concentration of such intravascular substances as hemoglobin and plasma proteins increases. We hypothesized that hemoconcentration would be associated with worsening renal function and possibly would provide insight into the relationship between aggressive decongestion and outcomes.
W orsening renal function (WRF) during the treatment of acute decompensated heart failure is a common condition complicating approximately one third of heart failure admissions and is associated with increased length of stay, increased readmission rate, and decreased short-and longterm survival. [1] [2] [3] [4] Historically, mechanisms invoked to explain WRF have centered on hemodynamic perturbations such as reduced cardiac index and overaggressive reduction in filling pressures. However, these theories have not been confirmed in recent publications. [5] [6] [7] [8] Notably, Mullens and colleagues found that patients with the highest admission cardiac indexes and highest discharge right atrial pressure actually had the greatest incidence of WRF. 6 Although these studies have provided strong evidence that diminished cardiac output is not the primary driver of cardiorenal interactions, little can be concluded about the importance of effective intravascular volume depletion as a causative mechanism for WRF. In these publications, right-and left-sided cardiac filling pressures were the only surrogates for intravascular volume reported. Given that the majority of blood volume is located in the venous system where pressure and volume have little correlation, the lack of association between WRF and significant reduction in filling pressures does not exclude intravascular volume depletion as a relevant mechanism governing cardiorenal interactions. 9 
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During diuresis, fluid is directly removed from the intravascular compartment into the urine via the kidneys. The rate at which fluid from the extravascular compartment such as peripheral edema or ascites can replace the loss in plasma volume governs the degree of intravascular volume contrac-tion that occurs. If fluid is removed too quickly or to a greater extent than fluid is replaced into the vascular space, then intravascular substances such as red blood cells and plasma proteins concentrate. For quite some time, the nephrology community has used changes in concentration of blood components such as red blood cells and plasma proteins to guide ultrafiltration rates in an effort to avoid intradialytic hypotension and symptoms of intravascular volume depletion. 10 -12 It has been proposed that these techniques could be extrapolated to the guidance of fluid removal during the treatment of acute decompensated heart failure, potentially allowing the avoidance of WRF and providing a physiologically relevant end point for fluid removal. 13 We hypothesized that if intravascular volume depletion is a relevant mechanism in cardiorenal interactions, hemoconcentration would be highly associated with changes in renal function during diuresis. Additionally, we hypothesized that hemoconcentration may more directly represent the aggressiveness of diuresis than surrogates such as changes in filling pressures or deterioration of renal function. As a result, hemoconcentration may provide insight into the relationship between the aggressiveness of decongestion and postdischarge outcomes, helping to inform the debate over whether WRF is a direct cause of adverse outcomes or simply a reflection of a more advanced disease state.
Methods
The Evaluation Study of Congestive Heart Failure and Pulmonary Artery Catheterization Effectiveness (ESCAPE) Trial was a National Heart, Lung, and Blood Institute (NHLBI)-sponsored, randomized, multicenter trial of therapy guided by pulmonary artery catheter (PAC) versus clinical assessment in hospitalized patients with acute decompensated heart failure. Methods and results have previously been published. 14, 15 Briefly, 433 patients were enrolled at 26 sites from January 2000 to November 2003. Inclusion criteria included an ejection fraction of Յ30%, systolic blood pressure of Յ125 mm Hg, and at least 1 sign and 1 symptom of congestion. Exclusion criteria included an admission creatinine level Ͼ3.5 mg/dL, use of dopamine or dobutamine Ͼ3 g ⅐ kg Ϫ1 ⅐ min Ϫ1 , or any use of milrinone before randomization. Patients were randomized to therapy guided by clinical assessment alone versus PAC and clinical assessment. Treatment goals were resolution of the signs and symptoms of congestion. In patients randomized to the PAC arm, additional goals of treatment were pulmonary capillary wedge pressure Յ15 mm Hg and right atrial pressure Յ8 mm Hg. Use of inotropes was "explicitly" discouraged. The ESCAPE trial was conducted and supported by the NHLBI in collaboration with the ESCAPE study investigators. This manuscript was prepared using a limited-access data set obtained from the NHLBI and does not necessarily reflect the opinions or views of the ESCAPE investigators or the NHLBI. For the purposes of this analysis, patients with admission and discharge serum creatinine levels (nϭ401) and at least 1 baseline/discharge pair of hematocrit (nϭ324), albumin (nϭ157), or total protein (nϭ142) laboratory values were included in the analysis. In total, 336 patients met these combined criteria. Improved renal function (IRF) was defined as a Ն20% increase and WRF as a Ն20% decrease in estimated glomerular filtration rate (GFR) from baseline to discharge. GFR was estimated from the 4-variable Modification of Diet in Renal Disease study equation. 16 This study was approved by the institutional review committee.
Statistical Methods
Values reported are meanϮSD and percentile unless otherwise noted. Independent Student t test or the Mann-Whitney U test was used to compare means of independent continuous variables. The Using backward selection and starting with the variable with the largest P value, we retained variables that altered the HR by Ͼ10% in the final model. Proportional-hazards models were subjected to 1000 bootstrap replications (with replacement). P values and 95% confidence intervals (CIs) were derived from these 1000 replications. Additionally, the effect of in-hospital characteristics that could plausibly influence survival was analyzed with forced-entry Cox proportional modeling. The proportionalhazards assumption was tested by visual inspection of log-minus-log survival plots. In the case of continuous variables or ambiguous log-minus-log plots, the proportional-hazards assumption was formally tested through the use of time-dependent variables representing the product of time and the covariate. The main effects and all covariates were not found to be in violation of the proportionalhazards assumption. Statistical analysis was performed with SPSS version 17.0 (SPSS Inc, Chicago, Ill), and significance was defined as 2-tailed value of PϽ0.05.
Results
Baseline characteristics of the overall trial population and their interaction with PAC use have been previously reported. 15 Characteristics of the 336 patients in the present substudy are described in Table 1 . Additionally, Nohria et al 8 have previously described the lack of association between PACderived hemodynamic variables and the development of WRF in this population. In the overall ESCAPE trial population, there were no significant differences in the rate of WRF, IRF, or mortality between patients who did or did not have pairs of baseline/discharge hematocrit, albumin, or total protein laboratory values available (data not shown).
There were no significant changes in baseline-to-discharge hematocrit (Pϭ0.44), albumin (Pϭ0.84), or total protein (Pϭ0.96). There was no correlation between admission hematocrit (rϭϪ0.05, Pϭ0.34), albumin (rϭϪ0.008, Pϭ0.90), or total protein (rϭϪ0.007, Pϭ0.91) with admission-to-discharge change in GFR. However, the mean increases in change in albumin (4.1Ϯ16.6% versus Ϫ3.4Ϯ12.7%; Pϭ0.002) and total protein (3.1Ϯ22.6% versus Ϫ1.9Ϯ10.4%; Pϭ0.003) were significantly greater in patients who experienced a reduction in GFR during hospitalization. Mean change in hematocrit was greater in patients with a reduction in GFR; however, this finding did not meet statistical significance (1.9Ϯ12.1% versus 0.3Ϯ12.5%; Pϭ0.055). Changes in blood component concentration were strongly associated with the direction of change in renal function, and the odds for deterioration in renal function were substantially higher for patients in the top tertile of change in albumin, total protein, or hematocrit ( 
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criminative ability between patients developing WRF versus IRF. Notably, the odds for a significant worsening versus improvement in GFR were 43.5 (PϽ0.001) times higher in patients with Ն2 of the 3 variables in the highest tertile (compared with patients with Ն2 of 3 not in the highest tertile). In those with all 3 measures in the highest tertile (nϭ22), none experienced IRF compared with 57.1% in patients with all 3 in the lowest tertile (nϭ14; PϽ0.001). The mean baseline-to-discharge change in GFR was also significantly associated with hemoconcentration ( Figure 1 ). Consistent with previous reports from the ESCAPE trial, PAC-derived parameters at baseline and final measurement or change from baseline to final measurement had no correlation with baseline-to-discharge change in renal function (PϾ0.10 for all). Additionally, right atrial pressure at baseline (Pϭ0.53), at the final measurement (Pϭ0.10), or its associated change (Pϭ0.36) was not different between patients with and without WRF. Similarly, pulmonary capillary wedge pressure at baseline (Pϭ0.32), at the final measurement (Pϭ0.40), or its associated change (Pϭ0.53) was also not significantly different between groups. In addition, the above associations were not significant for IRF (PϾ0.5 for all).
Given the strong association between the direction of change in renal function and the presence of Ն2 of 3 measures of hemoconcentration in the highest tertile, these patients were considered to have definitive evidence of hemoconcentration, and this definition was used in subsequent analyses. Characteristics of patients with and without hemoconcentration are presented in Table 1 . Consistent with a more aggressive diuresis, the patients with hemoconcentration were treated with significantly higher loop diuretic doses, had a greater total weight loss/rate of weight loss, had a larger total volume of diuresis/rate of diuresis, and experienced greater baseline-to-PAC-removal decreases in right atrial pressure and pulmonary capillary wedge pressure (Tables 1  and 3 ). Measures of disease severity such as hemoglobin, ejection fraction, maximum oxygen uptake, B-type natriuretic peptide level, New York Heart Association class, use of intravenous inotropes/vasodilators, and baseline evidencebased medication use were similar between groups (Table 1) . Notable exceptions were slightly higher baseline serum sodium and a significantly higher GFR in the group with hemoconcentration (Table 1) . However, by the time of discharge, these differences were no longer significant (Pϭ0.67 and Pϭ0.46 for sodium and GFR, respectively). Additionally, the group experiencing hemoconcentration had a lower baseline cardiac index, higher baseline loop diuretic use, and significantly higher prevalence of baseline pulmonary rales in more than one third of the lung fields. The discharge use of angiotensin-converting enzyme inhibitors/ receptor blockers (Pϭ0.83), ␤-blockers (Pϭ0.79), thiazide diuretics (Pϭ0.88), and loop diuretic dosage (Pϭ0.68) was similar between groups.
Association With Mortality
Consistent with findings in the overall ESCAPE population, WRF did not have a statistically significant association with mortality in the current subset of patients (HRϭ1.6; Pϭ0.11; n eventsϭ64, 19.3%). Admission serum hematocrit (Pϭ0.39), albumin (Pϭ0.98), and total protein (Pϭ0.28) levels were not associated with survival. Hemoconcentration, however, was associated with a substan- (Table 4) .
Discussion
The principal finding of this study is validation of the concept that the concentration of intravascular substances such as red blood cells and serum proteins during the treatment of acute decompensated heart failure provides substantial physiologically relevant information. Hemoconcentration appears to be related to the aggressiveness of diuresis and is associated with higher doses of loop diuretics, greater net weight/fluid loss, higher rate of weight/fluid loss, and greater reductions in right atrial pressure and pulmonary capillary wedge pressure. In patients who experienced hemoconcentration, the odds for Values represent meanϮSD or percent. Hemoconcentration was defined as Ն2 of 3 of change in total protein, in albumin, or in hematocrit in the highest quartile. No hemoconcentration was defined as Ն2 of 3 of the above variables not in the top tertile. *Significant.
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deterioration in renal function were substantially increased, lending credence to the theory that intravascular volume depletion is a highly relevant mechanism governing cardiorenal interactions. Additionally, hemoconcentration was associated with a substantially lower risk of mortality, raising the question of whether aggressive decongestion, even in the setting of worsened renal outcomes, may have a positive impact on survival. The finding that significant information related to cardiorenal interactions can be obtained from hemoconcentration, when no such data have been found in PAC-derived cardiac filling pressures, is not surprising given that pressure has little correlation with volume in the venous system. 9, [17] [18] [19] The venous system is made up of the most compliant vessels in the body (Ϸ30 times that of the arteries), and Ͼ70% of total blood volume resides in the venous compartment. 9 This great compliance facilitates a relative pressure-volume disconnect, allowing large changes in blood volume to be associated with small changes in pressure. In line with this physiology, filling pressures such as central venous pressure and pulmonary capillary wedge pressure have repeatedly demonstrated little to no correlation with measures of volume status such as circulating blood volume and hemodynamic response to fluid challenge. 17,19 -25 In addition to the inherently compliant nature of these vessels, their capacity can be greatly altered by changes in sympathetic tone, with increased tone leading to a significantly altered pressure-volume relationship. 9,18,26 -29 This is particularly relevant because the final common pathway for changes in renal function during the treatment of decompensated heart failure is thought to be secondary to neurohormonally mediated decreases in GFR, a form of renal dysfunction often referred to as vasomotor nephropathy. 30 Teleologically, it is likely that the same cascade of neurohormonal reflexes activated during volume loss, which serve to defend cardiac output and filling pressures, are also responsible for reduction in GFR and the sodium-avid state characteristic of vasomotor nephropathy. Given the remarkable compliance and susceptibility to sympathetically mediated alterations in pressure-volume relationship exhibited in the venous system, it becomes quite understandable how hemoconcentration could be highly associated with changes in renal function and PAC-derived filling pressures are not.
Our primary objective in analyzing the association between mortality and hemoconcentration was to discern whether the negative association often observed between survival and WRF is secondary to the actual harm caused to the patient by aggressive diuresis or whether the occurrence of WRF in this setting is simply a reflection of a more advanced disease state. We reasoned that hemoconcentration would likely be tightly coupled to the aggressiveness of decongestion and less so to the disease burden of the patient. This was supported by the very similar overall characteristics of patients with and without hemoconcentration with the exclusion of diuresisrelated variables such as loop diuretic dose, weight/volume loss, rate of weight/volume loss, and reduction in filling pressures (all of which were greater in the hemoconcentration group). A strong relationship between hemoconcentration and ␦HCT indicates baseline-to-discharge change in hematocrit; ␦ALB, baselineto-discharge change in albumin; and ␦TP, baseline-to-discharge change in total protein. All HRs are after adjustment of baseline characteristics (GFR, loop diuretic dose, sodium, age, ischemic origin, idiopathic origin, significant ascites, severe edema, jugular venous distention Ͼ12 cm water, respiratory rate, angiotensin-converting enzyme inhibitor/angiotensin receptor blocker use, and fatigue at rest). *Significant.
the direction of change in renal function was observed; however, the polarity of association with mortality was strongly opposed to that associated with WRF. These data suggest that aggressive diuresis is likely not primarily responsible for the excess mortality noted in patients with WRF. The association between decreased mortality and hemoconcentration is a provocative finding. High-dose loop diuretics have repeatedly been associated with increased mortality. [31] [32] [33] Despite the fact that patients with hemoconcentration were administered higher doses of loop diuretics, they had a profoundly lower mortality. Adjusting for baseline characteristics actually tended to strengthen the association with mortality, suggesting that, if anything, the group with hemoconcentration may actually have been "sicker." Taken as a whole, these observations suggest that aggressive decongestion itself may be at least partially driving the association with improved survival and hemoconcentration. It has been proposed that patients discharged with elevated filling pressures have a subsequent greater risk of mortality and that congestion may directly participate in the pathophysiological processes implicated in heart failure progression. 13,30,34 -36 Although adjustment for a host of prognostically relevant variables was performed, it is impossible in an observational study to definitively demonstrate that hemoconcentration does not somehow identify an overall healthier group of patients. Significant information related to this question may be gleaned from the ongoing Cardiorenal Rescue Study in Acute Decompensated Heart Failure (CARESS) study and the recently completed Diuretic Optimization Strategies Evaluation (DOSE) trial, both of which compare aggressive strategies of decongestion. If the association between hemoconcentration and improved postdischarge mortality is replicated, a randomized trial tailoring therapy based on hemoconcentration may be warranted.
Limitations
The limited number of patients in the ESCAPE data set with complete sets of laboratory values limits power. Although limited power did not affect the primary analysis, likely as a result of the large effect size, associations with smaller effect sizes may not be apparent in this analysis. Additionally, it is possible that some of the modestly significant associations may have arisen as a result of chance owing to multiple comparisons and should be interpreted with caution. Moreover, because of the small absolute number of terminal events and the large number of covariates, multivariate models may be unstable and may not generalize well to external data sets. The primary purpose for these models was to thoroughly control for baseline characteristics to evaluate the concept that hemoconcentration was not simply a surrogate for healthier patients in this data set. Additionally, the availability of only baseline and discharge markers of hemoconcentration limits the ability to determine temporal relationships between hemoconcentration and changes in renal function. Although the ESCAPE trial is one of the largest contemporary data sets with detailed hemodynamic information on decompensated heart failure, by nature of the trial design, PAC data are available only on slightly more than half the patients, limiting power. Additionally, because the treating physicians were not blinded to either renal or PAC data, it is likely that treatment strategies were significantly modified in response to those variables. Moreover, hematocrit, albumin, and total protein are at best imperfect measures of hemoconcentration; superior metrics likely exist. Although strong associations were found between changes in the above markers and several clinical variables/outcomes, the absolute change in these markers was small and thus potentially difficult to apply to individual patients.
Conclusions
Results from this cohort support the notion that a reduction in intravascular volume sufficient to cause hemoconcentration is strongly associated with changes in renal function during the treatment of acute decompensated heart failure. This concentration of blood components appeared to be related to the aggressiveness of diuresis and suggests that intravascular volume depletion may be a highly relevant mechanism governing cardiorenal interactions. Additionally, hemoconcentration was associated with a substantially lower risk of mortality, raising the possibility that aggressive decongestion, even in the face of worsened renal outcomes, may affect postdischarge survival positively. Although these results are internally consistent and in line with plausible pathophysiological mechanisms, the sample size is small, and methodologic limitations are significant. As a result, these findings should challenge, rather than change, current conceptions and require validation in additional cohorts. Future research is necessary to replicate these findings and to identify optimal markers of hemoconcentration. If future investigation replicates these results, exploration of the concept of tailored therapy guided by hemoconcentration may be warranted.
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